Idorsia: Positive Phase 3 study with aprocitentan shows antihypertensive efficacy

 

• Aprocitentan reduces blood pressure compared to placebo by week 4 of treatment, the effect is maintained and confirmed over a period of 48 weeks, and is generally well tolerated with no major safety concerns
• Primary and key secondary endpoints were met with statistical significance and clinically meaningful results – the effect was consistent across multiple endpoints and methodologies of blood pressure monitoring
• Idorsia to host an investor webcast to discuss PRECISION top-line results tomorrow May 24 at 14:00hrs CEST

Investor webcast
An investor conference call and webcast will be held to discuss the Phase 3 results with aprocitentan. The call will start with presentations by senior management, followed by a Q&A session (live access to the speakers).

Date: Tuesday May 24, 2022
Time: 14:00 CEST | 13:00 BST | 08:00 EDT

Webcast participants should visit Idorsia's website www.idorsia.com 10-15 minutes before the webcast is due to start.
Conference call participants should start calling the number below 10-15 minutes before the conference is due to start.

Dial-in: CH: +41 (0)44 580 71 45 | UK: +44 (0) 2071 928338| US: +1 646 741 3167
PIN: 4838017

https://www.marketscreener.com/quote/stock/IDORSIA-LTD-35837944/news/Positive-Phase-3-study-with-aprocitentan-demonstrates-significant-antihypertensive-efficacy-in-patie-40512879/